Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 30 Carcinoma, Hepatocellular 13 Rectal Neoplasms 5 Colonic Neoplasms 5 Sarcoma, Ewing 4 Osteosarcoma 4 Glioblastoma 4 Gastrointestinal Stromal Tumors 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Neoplasm Metastasis 3 Sarcoma 2 Neoplasms 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Esophageal Neoplasms 2 Chondrosarcoma 2 Bone Neoplasms 2 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Spinocerebellar Degenerations 1 Solid Malignant Tumors 1 Small Cell Lung Carcinoma 1 Recurrence 1 Piebaldism 1 Patient Compliance 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1

Interventions

Cyclophosphamide 51 fludarabine 37 Dexamethasone 35 venetoclax 30 pembrolizumab 26 Rituximab 21 Lenalidomide 18 pomalidomide 17 Gemcitabine 17 fludarabine phosphate 15 Etoposide 14 Cytarabine 13 daratumumab 11 carfilzomib 11 Temozolomide 11 Cisplatin 10 Calcium Dobesilate 10 glofitamab 9 Nivolumab 9 Injections 9 Azacitidine 9 selinexor 8 Vincristine 8 Immunotherapy, Adoptive 8 Carboplatin 8 Bortezomib 8 obinutuzumab 7 cemiplimab 7 Drug Therapy 7 Bevacizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × regorafenib × 1 year × Clear all

NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡